Zebrafish angiogenesis: a new model for drug screening

Area of Science:

• Developmental biology
• Cancer research
• Pharmacology

Background:

• Tumor growth necessitates angiogenesis, making its inhibition a key cancer therapy strategy.
• Existing angiogenesis assays are complex and impractical for high-throughput drug screening.
• The zebrafish offers a potential whole-animal model for evaluating anti-angiogenic compounds.

Purpose of the Study:

• To validate the zebrafish embryo as a viable model for screening small molecules that inhibit angiogenesis.
• To assess the dose-dependent effects of known angiogenesis inhibitors in zebrafish.
• To confirm the responsiveness of zebrafish blood vessels to angiogenic stimuli.

Main Methods:

• Developing zebrafish embryos were exposed to small molecules in culture media.
• Subintestinal vessels (SIVs) were visualized microscopically to assess blood vessel formation.
• Known angiogenesis inhibitors (SU5416, TNP470) and human VEGF were administered to embryos.

Main Results:

• Both SU5416 and TNP470 reduced blood vessel formation in zebrafish embryos.
• Short exposure to SU5416 blocked new vessel formation, while TNP470 required continuous exposure.
• Human VEGF administration increased SIV formation, confirming embryo responsiveness.

Conclusions:

• The zebrafish embryo is a practical and effective whole-animal model for angiogenesis drug screening.
• This model allows for the observation of dose-dependent effects of anti-angiogenic compounds.
• Zebrafish vascular development is sensitive to both inhibition and stimulation of angiogenesis.